scorecardresearch
Tuesday, August 26, 2025
TopicDCGI

Topic: DCGI

DCGI approves use of favipiravir for restricted emergency use in moderate Covid-19 cases

To address urgency of rising Covid-19 cases, Drug Controller General of India fast-tracked permission to Glenmark Pharmaceuticals to manufacture & market favipiravir tablets.

After US red-flag, Modi govt asks states to check samples of acidity drug for cancer agent

Drug Controller General of India has written to state drug regulators, asking them to alert manufacturers about Ranitidine & take steps to ensure patient safety.

India’s drug regulator warns Amazon against selling adulterated cosmetics

Raids by Drug Controller General of India (DCGI) inspectors found unlicenced goods were beng sold on e-commerce websites including Amazon. 

On Camera

India will absorb Trump tariff impact due to its Achilles’ heel

Like China, India remains a big domestic market, which will continue to attract investment, but the US tariffs will make India unattractive for future investments.

New insolvency frameworks to shorter timelines, how 2025 amendment bill proposes to transform IBC

New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.

Was Pahalgam a trap by Pakistan to lure India into a conflict? An Army officer thinks so

Speaking at tri-service seminar, Major General SP Vishwasrao also said farmers’ protest, anti-CAA agitation & situation in Manipur was part of ‘larger ploy’ to destabilise India.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.